Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
Details for Australian Patent Application No. 2002339845 (hide)
International Classifications
Event Publications
27 February 2003 Complete Application Filed
Priority application(s): 60/309,516 03.08.01 US
29 May 2003 Application Open to Public Inspection
Published as AU-B-2002339845
23 March 2006 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired
This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.
6 April 2006 Corrigenda
Applications Lapsed, Refused or Withdrawn, Patents Ceased or Expired - 2002 Delete all reference to Application No. 2002339845
26 March 2009 Application Accepted
Published as AU-B-2002339845
23 July 2009 Standard Patent Sealed
6 September 2012 Application for Amendment
The nature of the amendment is: Amend the Patentee to read Roche GlycArt AG . Address for service in Australia - Peter Maxwell & Associates Level 6 60 Pitt Street Sydney NSW 2000 2004
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2002339844-SCREENING AND THERAPEUTIC METHODS FOR PROMOTING WAKEFULNESS AND SLEEP
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
![](/images/main/3dbox_small.png)
- Editable Word format reports
- For IP Professionals
- Multiuser